A new article published in the American Journal of Obstetrics and Gynecology reported uterine fibroids as the most common benign pelvic tumors affecting nearly 70% of Caucasian women and more than 80% of African American women in the United States by 50 years of age. These fibroids cause significant morbidity – up to 50% of women with fibroids experience symptoms, including heavy menstrual bleeding, dysmenorrhea, and reproductive dysfunction. Currently, the primary management strategy for this benign tumor is surgical; uterine fibroids account for approximately one-third of all hysterectomies annually, in the United States. The article disclosed that until recently, medical management options have been of limited value due to moderate efficacy and/or associated adverse effects of medications. Thus, it was stated that novel therapies in late-stage development, including oral treatments, may offer better long-term medical management options for uterine fibroids.